NEUmiRNA A/S (Copenhagen, Denmark) is developing RNA therapies with the ambition to treat certain neurological disorders.
Many patients with neurological diseases have limited treatment options or are no longer responding to the available medication. NEUmiRNA’s lead program is an anti-miRNA treatment for patients with epilepsy. The company is founded by Henrik Klitgaard who is world renowned for his work in epilepsy research and drug development, and Sakari Kauppinen who brings his knowledge in RNA/LNA based therapies.
For more information, please contact:
Phone +45 2422 1969